MET D1228N突变是伴有MET Y1003H突变的NSCLC患者克唑替尼耐药的后天潜在机制

IF 5.1 Q1 ONCOLOGY

Lung Cancer: Targets and Therapy Pub Date : 2024-08-27 eCollection Date: 2024-01-01 DOI:10.2147/LCTT.S467584

Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu

{"title":"MET D1228N突变是伴有MET Y1003H突变的NSCLC患者克唑替尼耐药的后天潜在机制","authors":"Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu","doi":"10.2147/LCTT.S467584","DOIUrl":null,"url":null,"abstract":"Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"15 ","pages":"123-128"},"PeriodicalIF":5.1000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365520/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.\",\"authors\":\"Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu\",\"doi\":\"10.2147/LCTT.S467584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":\"15 \",\"pages\":\"123-128\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365520/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S467584\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S467584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

间充质-上皮转化（MET）基因已被确定为有希望的治疗靶点。然而，不同位点的MET突变对MET抑制的效果不同。在此，我们报告了一名携带MET Y1003H突变的非小细胞肺癌（NSCLC）患者，该患者对克唑替尼获得了持久的部分应答，PFS达22.4个月。此外，我们还首次报道了在一名MET Y1003H突变患者的疾病进展过程中发现MET D1228N可能是克唑替尼获得性耐药的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lung Cancer: Targets and Therapy Medicine-Oncology

CiteScore

8.10

自引率

0.00%

发文量

审稿时长

16 weeks